{"id":124785,"date":"2021-07-10T21:22:18","date_gmt":"2021-07-11T04:22:18","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2021\/07\/fda-oks-bispecific-antibody-for-rare-lung-cancer-subtype"},"modified":"2021-07-10T21:22:18","modified_gmt":"2021-07-11T04:22:18","slug":"fda-oks-bispecific-antibody-for-rare-lung-cancer-subtype","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2021\/07\/fda-oks-bispecific-antibody-for-rare-lung-cancer-subtype","title":{"rendered":"FDA OKs Bispecific Antibody for Rare Lung Cancer Subtype"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/fda-oks-bispecific-antibody-for-rare-lung-cancer-subtype2.jpg\"><\/a><\/p>\n<p>The overall response rate in the trial population was 40% (95% CI 29%-51%). Median duration of response was 11.1 months (95% CI 6.9-not evaluable), with nearly two-thirds of patients having a duration of response of at least 6 months.<\/p>\n<hr>\n<p>The FDA <a href=\"https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-targeted-therapy-subset-non-small-cell-lung-cancer\" target=\"_blank\">approved amivantamab-vmjw<\/a> (Rybrevant) on Friday as the first treatment for patients with non-small cell lung cancer (NSCLC) harboring <em>EGFR<\/em> exon 20 insertion mutations.<\/p>\n<p>Amivantamab is a bispecific antibody that targets EGFR and mesenchymal-epithelial transition factor pathways. <em>EGFR<\/em> exon 20 insertion mutations occur in approximately 2% to 3% of NSCLC patients, and are associated with rapid cell growth.<\/p>\n<p>\u201cAdvances in precision oncology continue to facilitate drug development, allowing diseases like lung cancer to be subset into biomarker-defined populations appropriate for targeted therapies,\u201d said Julia Beaver, MD, chief of medical oncology in the FDA\u2019s Oncology Center of Excellence, in a statement. \u201cWith today\u2019s approval, for the first time, patients with non-small cell lung cancer with <em>EGFR<\/em> exon 20 insertion mutations will have a targeted treatment option.\u201d<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The overall response rate in the trial population was 40% (95% CI 29%-51%). Median duration of response was 11.1 months (95% CI 6.9-not evaluable), with nearly two-thirds of patients having a duration of response of at least 6 months. The FDA approved amivantamab-vmjw (Rybrevant) on Friday as the first treatment for patients with non-small cell [\u2026]<\/p>\n","protected":false},"author":621,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-124785","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/124785","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/621"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=124785"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/124785\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=124785"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=124785"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=124785"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}